R&D News | pharmaphorum

News

Acquisitive Lilly offers $2.88bn for Merida Bio

Lilly has continued its lengthy streak of acquisitions in 2026 with a $2.88 billion agreement to buy immunology and inflammation specialist Merida.

News

ESC26: Isomab safety evidence on blood vessel growth for CAD

Isomab has presented landmark safety data at ESC, clearing the path for next-generation therapies to promote blood vessel growth in CAD.

News

AZ, Amgen positive Ph3 results for Tezspire in EoE

AstraZeneca and Amgen have announced the first Phase III results for Tezspire (tezepelumab) in eosinophilic oesophagitis (EoE).

News

An older woman with rheumatoid arthritis holds her wrist in pain while sat in an armchair

Spyre deprioritises arthritis drug after Phase 2 results

Spyre Therapeutics’ hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road.

News

Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD

Entropy signs Pre-CTA with UCSF to develop a US-based Phase 2 trial comparing IV psilocin treatment directly against escitalopram (Lexapro) in MDD.

News

The puzzle of Alzheimer's, HCP hand holds digital graphic of brain and missing puzzle piece

Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2

Nxera Pharma has announced that partner Neurocrine Biosciences has received IND Acceptance from the FDA a Ph2 of NBI-1117567 in Alzheimer's cognition.

Acquisitive Lilly offers $2.88bn for Merida Bio

ESC26: Isomab safety evidence on blood vessel growth for CAD

AZ, Amgen positive Ph3 results for Tezspire in EoE

Spyre deprioritises arthritis drug after Phase 2 results

Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD

Neurocrine receives FDA IND Acceptance for Alzheimer’s Ph2

Novartis sets sights on new oral MS drug after phase 3 wins

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks